Headquarters: Marburg, Germany
Offering: RiaSTAP® (Human Fibrinogen Concentrate, lyophilized powder for injection)
Detailed Case Study
In 2025, CSL Behring GmbH — one of the world’s leading biopharmaceutical companies specializing in plasma-derived and recombinant therapeutic products — took a decisive step to meet the escalating global demand for human fibrinogen concentrates. With congenital and acquired fibrinogen deficiencies gaining increasing clinical recognition, especially in trauma, postpartum hemorrhage (PPH), and surgical bleeding, healthcare systems around the world were facing supply constraints for reliable, high-purity fibrinogen therapies. Recognizing this challenge, CSL Behring announced a major expansion of its RiaSTAP® production capacity, focusing on accessibility, safety, and scalability.
The expansion centered around the commissioning of a state-of-the-art plasma fractionation and purification facility in Bern, Switzerland. This new infrastructure was equipped with advanced viral inactivation technologies, chromatography systems, and nanofiltration units, ensuring that RiaSTAP® maintained the highest standards of safety and consistency. The project represented CSL’s broader strategic commitment to global plasma security and its “Patient First” mission — ensuring that life-saving therapies reach those in need, regardless of geography.
A key objective of the 2025 initiative was to bridge treatment gaps in Asia-Pacific and Latin America, regions that historically faced challenges in fibrinogen availability due to limited plasma collection and regulatory complexities. The new facility enabled a 35% increase in global supply of RiaSTAP®, effectively expanding distribution networks to markets including India, Japan, Australia, and Brazil. The expansion also included localized regulatory collaborations and clinician training programs to ensure proper administration and monitoring of fibrinogen replacement therapy.
Beyond physical expansion, CSL Behring integrated digital process optimization into its manufacturing system. Using predictive analytics and AI-driven quality monitoring, the company improved production yields while minimizing plasma wastage — a critical factor in an industry dependent on human plasma donations. This approach not only reduced production bottlenecks but also enhanced CSL’s ability to forecast regional demands more accurately.
By mid-2025, the operational efficiency and added capacity began to translate into measurable patient impact. Emerging markets, which previously experienced long waiting periods for fibrinogen concentrate imports, saw an average 40% reduction in patient treatment wait times. Hospitals reported improved treatment continuity for rare congenital fibrinogen deficiency (CFD) cases, as well as faster response in managing severe trauma and bleeding complications. The initiative also strengthened CSL Behring’s relationships with health ministries, NGOs, and transfusion centers worldwide, further embedding the company’s role in global hemostasis management.
Outcome
The expansion of RiaSTAP® production delivered a series of positive outcomes both clinically and operationally.
-
Increased global availability: CSL successfully expanded its fibrinogen concentrate output by 35%, allowing faster response to both congenital and acquired deficiency cases.
-
Improved treatment accessibility: The project enabled healthcare providers in resource-limited countries to access plasma-derived fibrinogen without relying on emergency imports or cryoprecipitate substitutes.
-
Reduced patient waiting time: Treatment waiting periods in Asia-Pacific and Latin America were reduced by 40%, significantly improving patient outcomes and reducing bleeding-related mortality.
-
Operational sustainability: With automated manufacturing and optimized plasma utilization, CSL reduced its production costs and carbon footprint while maintaining premium product quality.
These outcomes positioned CSL Behring not just as a supplier but as a strategic healthcare partner working toward global bleeding disorder management.
Protectional
Maintaining the highest level of safety and quality was central to CSL’s 2025 expansion. Every stage of RiaSTAP® production adhered to EU-GMP (Good Manufacturing Practice) standards and ICH Q5A viral safety protocols. The company implemented a robust traceability framework, allowing for end-to-end monitoring from plasma donation through purification to product release.
The facility employed multi-step viral inactivation and removal methods, including solvent-detergent treatment, pasteurization, and nanofiltration, ensuring comprehensive viral clearance. This approach aligned with international best practices and met regulatory expectations from the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
In addition, CSL reinforced its pharmacovigilance infrastructure, enabling real-time monitoring of post-market safety data through digital surveillance systems. This ensured that any potential adverse event associated with fibrinogen therapy was quickly detected and addressed, maintaining patient trust and clinical confidence.
Impact on the Market
The expansion of RiaSTAP® production had a profound impact on the Human Fibrinogen Concentrates Market. CSL Behring already held a strong position as a global leader, but this initiative further solidified its dominance by addressing one of the most pressing issues — supply security.
The company’s ability to deliver consistent quality at scale raised the competitive bar for other biopharma manufacturers. It inspired renewed focus on technological upgrades, clinical research, and regional partnerships among competitors. Moreover, CSL’s initiative catalyzed broader market confidence in plasma-derived fibrinogen therapies, particularly in critical care and surgical bleeding management, where cryoprecipitate had long been the default treatment despite safety limitations.
Clinicians and healthcare policymakers began prioritizing human fibrinogen concentrates in national hemostatic care guidelines, recognizing their standardized potency and viral safety advantages. Consequently, market demand expanded steadily through 2025, with hospitals shifting procurement budgets toward high-purity fibrinogen concentrates.
Financial After Implementation
Financially, the 2025 expansion proved to be a strategic success for CSL Behring. The company reported a 12% year-on-year increase in revenue from its fibrinogen product portfolio. This growth was driven primarily by expanding international market share, improved production efficiency, and broader adoption in both congenital and acquired deficiency indications.
RiaSTAP®’s success also had a ripple effect across CSL’s broader immunology and hematology business segments, strengthening its financial resilience in a competitive biologics landscape. The project’s operational gains — including reduced plasma wastage and higher production throughput improved gross margins, making the fibrinogen segment one of CSL’s most profitable therapeutic areas.
Conclusion
CSL Behring’s strategic expansion of RiaSTAP® manufacturing capacity exemplified a forward-thinking approach to global healthcare delivery. Through innovation, regulatory excellence, and an unwavering commitment to patient access, the company not only addressed an urgent supply gap but also set new standards for quality and efficiency in the human fibrinogen concentrates market.
The case of CSL Behring illustrates how sustained investment in manufacturing infrastructure, combined with strong compliance and digital transformation, can simultaneously improve patient outcomes and drive long-term business growth, reinforcing its position as a global leader in plasma therapeutics.
Dive into the full analysis here: https://www.precedenceresearch.com/human-fibrinogen-concentrates-market